Sigyn Therapeutics (SIGY) Change in Receivables (2016 - 2020)

Sigyn Therapeutics (SIGY) posted Change in Receivables of $756.0 for Q1 2020, down 23.94% sequentially from $994.0 in Q4 2018.

Sigyn Therapeutics (SIGY) Change in Receivables (2016 - 2020) Analysis & Trends

Sigyn Therapeutics has reported Change in Receivables for 4 years, with the latest figure at $756.0 in Q1 2020.

Quarterly Change in Receivables changed N/A year-over-year to $756.0 in Q1 2020, while the trailing twelve-month figure through Mar 2020 was -$20276.0 (changed N/A YoY) and the FY2018 annual result came in at -$7634.0, down 178.46% from the prior year.
Change in Receivables declined to $756.0 in Q1 2020 per SIGY's latest filing, from $994.0 in the prior quarter.
Over five years, Change in Receivables peaked at $107908.0 in Q1 2016 and troughed at -$45680.0 in Q3 2017.
A 4-year average of $11076.0 and a median of $875.0 in 2018 frame the typical range for Change in Receivables.
The widest YoY moves for Change in Receivables: up 113.09% in 2018, down 153.13% in 2018.
Over 4 years, Change in Receivables stood at $107908.0 in 2016, then plunged by 107.04% to -$7592.0 in 2017, then surged by 113.09% to $994.0 in 2018, then decreased by 23.94% to $756.0 in 2020.
According to Business Quant data, Change in Receivables over the past three periods registered $756.0, $994.0, and -$1911.0 for Q1 2020, Q4 2018, and Q3 2018 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Receivables (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	140.20 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	838.50 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-53.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	117.58 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	31.60 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	94.29 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	37.16 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Sigyn Therapeutics	48,161.31	-37,409.69	-	-

Download Data